Table 4.
Compare treatments of survivors with deceased MF patients after CNS metastasis.
| Survivor (n = 10) | Deceased (n = 54) | p-value | |
|---|---|---|---|
| Temozol | 2 | 2 | 0.1 |
| Single Agent Chemotherapy | 1 | 14 | 0.15 |
| MTX (intrathecal/IV/PO) | 2 | 18 | 0.2 |
| Surgery | 2 | 3 | 0.2 |
| Cranial or Systemic Radiotherapy | 7 | 24 | 0.41 |
| Systemic Steroids | 6 | 20 | 0.44 |
| Palliation | 0 | 2 | 0.49 |
| Topical Mustard/Carmustine | 0 | 1 | 0.63 |
| IL2 | 0 | 1 | 0.63 |
| IFN | 0 | 1 | 0.63 |
| Vitamin A Derivatives | 1 | 0 | 0.63 |
| HDACi (Vorinostat/Romidepsin) | 1 | 0 | 0.63 |
| Arsenic | 1 | 0 | 0.63 |
| Combination Chemotherapy | 2 | 11 | 0.71 |